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Antimalarial drug resistance means delayed malaria parasites clearance from the 
peripheral blood of a patient treated with the drug. Artemisinin resistance (AR) has 
developed in Southeast Asia owing to mutations in parasite genes. From historical spread 
of drug resistance across Asia to Africa, the spread of resistance to artemisinin 
combination therapy across Asia to Africa is imminent. This study evaluates molecular 
markers associated with artemisinin derivatives and partner drugs commonly used in 
Africa and provides data on the Plasmodium falciparum multidrug resistant 1 (Pfmdr1) 
and the Kelch propeller (K13) gene mutation profile of few parasite isolates from Ota, 
Southwest Nigeria. Parasites from a total of 210 of 360 blood samples diagnosed with 
malaria were studied; DNA was extracted and amplified in nested Polymerase Chain 
Reaction (PCR) with primers specific for Plasmodium falciparum multidrug resistant 
(Pfmdr1) and the Kelch propeller (K13) genes. Amplicons were resolved on a 2% agarose 
gel and 5µl secondary amplicon were digested using restriction enzymes AflIII to detect 
polymorphism on codon 86 in the Pfmdr1 gene or sequenced to detect SNPs in the genes 
from few isolates (10%). The result of this study showed high prevalence (100%) of 
Pfmdr1 86Tyr mutant allele observed in all of the 4 isolates sequenced. For K13 gene, 13 
unique mutations that have not been previously reported to be associated with artemisinin 
resistance were observed from one of the isolates but no marker of AR was observed. In 
conclusion, parasite isolates from this endemic area harbor high Pfmdr1 mutations and 
other mutations on K13 with unknown consequences, which may influence clinical 
responses to artemisinin and its partner drug.
